Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRPE-3-Cr(III) is an experimental chromium(III) coordination complex of SRPE-3, an enzymatic product of sulfated rhamnose polysaccharide derived from the green alga *Enteromorpha prolifera*. In a high-fat, high-sucrose diet-induced mouse model of type 2 diabetes mellitus, it reduced blood glucose, adiposity, triglycerides, total cholesterol, and LDL cholesterol while increasing HDL cholesterol. The reported preclinical findings also included lower leptin, resistin, tumor necrosis factor alpha, hepatic fatty acid synthase, and acetyl-CoA carboxylase activity, alongside increased adiponectin. It is an early academic research compound rather than an approved or clinically established medicine. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077238/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRPE-3-Cr(III).